Contact Us
Contact Us
Do you have questions about the study, screening, or your participation? Contact our team—we are here to help you.
Our mission
Promoting early screening for earlier intervention
Contact Us
Contact a member of our team
Our team is available to answer your questions about the FEDERATE-CAN study, early screening for type 1 diabetes, or participation in the project. Please feel free to write or call us. We will be happy to assist you.
Contact us by filling out this form
We are here
Montreal Clinical Research Institute (IRCM)
Our research centre
Montreal Clinical Research Institute (IRCM)
The IRCM is a leading research center dedicated to understanding and preventing chronic diseases. Their teams work together to drive science forward, improve public health, and bridge the gap between discoveries and patient needs.
Any questions?
Frequently asked questions
Yes, you can participate. If you decide to participate in the study, you agree to travel to the IRCM for all study visits. Only one visit is required if the screening test is negative.
The first visit lasts approximately 2 hours. The visit includes:
- Signing the consent form
- Completing questionnaires: Medical history, lifestyle, physical activity, diet, and mental health
- Various measurements: weight, blood pressure, waist circumference, glycation products
- Blood test: antibody testing for type 1 diabetes and other autoimmune diseases, liver and kidney function tests, cholesterol, etc.
Among all the tests performed, the only one that causes discomfort is the blood draw. All other tests should not cause any pain.
If a member of your family has type 1 diabetes and you test negative as an adult, your risk of developing the disease is the same as that of someone without risk factors, but it is not zero. However, in the absence of scientific data, current recommendations do not suggest retesting.
At present, there is no way to prevent the onset of type 1 diabetes. However, there is a Health Canada-approved treatment to delay its onset in those with early-stage disease. For more information, see the link SUPPORT for teplizumab.
You can contact our team at the following email address:
[email protected] or by phone at 514-987-5500 ext. 3295.
This research project is funded by Sanofi as part of an “Investigator-Initiated Research.” This means that the study is designed and conducted by independent researchers, not by the pharmaceutical company. The funding supports the research activities, but Sanofi is not involved in the design or conduct of the study, the analysis of the data, or the interpretation of the results. The researchers remain responsible for the project and are committed to following strict scientific and ethical standards to ensure the integrity and transparency of the results.
Once the study is completed, it will be important to continue regular follow-up to ensure that progression of type 1 diabetes is not missed. Your medical follow-up may be carried out either by your family physician if you have one, or by one of the clinician investigators involved in the study.
Didn’t find the answer to your question?
